Actinium Pharmaceuticals
Website to be confirmed.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals sits in Radiopharma Developer, a segment Bracken sees as structurally important to the radiopharma value chain.
Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.
What we're seeing
- Imaging Wire · 2026-01-20Actinium Pharmaceuticals closes Series C round to scale radiopharma manufacturingCoverage notes the company's growing footprint in the radioligand therapy space.
- STAT News · 2026-06-11Actinium Pharmaceuticals publishes dosimetry data at SNMMI 2026Industry observers expect more activity of this kind in the run-up to SNMMI 2026.
- Nuclear Medicine Today · 2026-07-22Actinium Pharmaceuticals files IND for next-generation PSMA-targeted agentDetails remain limited but analysts read the move as a positioning play ahead of pivotal data.
Mocked while we wire the Exa integration. Headlines are illustrative.
What we expect to see at the booth
Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.
A short Bracken POV will go here, drawing on our experience across this part of the radiopharma value chain. Specific commentary to be filled in by the team.
Editorial shown for exhibitors in Bracken's wheelhouse: radiopharma developers, isotope supply, CDMO/CMO, cyclotron, and imaging equipment.
Companies you may also want to visit.
AtomVie Global Radiopharma Inc.
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on AtomVie Global Radiopharma Inc..
View profile →Bayer Oncology
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Bayer Oncology.
View profile →BRACCO
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on BRACCO.
View profile →